Literature DB >> 18242497

Medical treatment of cholestatic liver disease.

Gustav Paumgartner1, Thomas Pusl.   

Abstract

In most cholestatic liver diseases the cause of the disease is not known and therapy can only be directed toward suppression of the pathogenetic processes and amelioration of the consequences of cholestasis. The recognition of adaptive-compensatory responses to cholestasis has become of major importance. They tend to minimize retention of bile acids and other potentially toxic solutes in the hepatocyte by limiting hepatocellular uptake, reducing bile acid synthesis, stimulating detoxification, and up-regulating alternative pathways for excretion. Some of the drugs used for the treatment of cholestatic liver diseases in an empiric way turned out to be modulators of nuclear receptors, which regulate these adaptive-compensatory responses. New drugs are being designed and tested along these lines and may be regarded as treatment opportunities of the future.

Entities:  

Mesh:

Year:  2008        PMID: 18242497     DOI: 10.1016/j.cld.2007.11.013

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  10 in total

1.  Crosstalk of liver, bile ducts and the gut.

Authors:  Ulrich Beuers
Journal:  Clin Rev Allergy Immunol       Date:  2009-02       Impact factor: 8.667

2.  Swertianlarin, isolated from Swertia mussotii Franch, increases detoxification enzymes and efflux transporters expression in rats.

Authors:  Xin-Chan Feng; Xiaohuang Du; Sheng Chen; Dongmei Yue; Ying Cheng; Liangjun Zhang; Yu Gao; Shaoxue Li; Lei Chen; Zhihong Peng; Yong Yang; Weizao Luo; Rongquan Wang; Wensheng Chen; Jin Chai
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

Review 3.  Recent developments in diagnostics and treatment of neonatal cholestasis.

Authors:  Amy G Feldman; Ronald J Sokol
Journal:  Semin Pediatr Surg       Date:  2020-07-23       Impact factor: 2.754

4.  The human UGT1A3 enzyme conjugates norursodeoxycholic acid into a C23-ester glucuronide in the liver.

Authors:  Jocelyn Trottier; Diala El Husseini; Martin Perreault; Sophie Pâquet; Patrick Caron; Sylvie Bourassa; Mélanie Verreault; Ted T Inaba; Guy G Poirier; Alain Bélanger; Chantal Guillemette; Michael Trauner; Olivier Barbier
Journal:  J Biol Chem       Date:  2009-11-04       Impact factor: 5.157

Review 5.  Nuclear receptors as therapeutic targets in cholestatic liver diseases.

Authors:  Gernot Zollner; Michael Trauner
Journal:  Br J Pharmacol       Date:  2009-01       Impact factor: 8.739

Review 6.  Medical treatment of primary sclerosing cholangitis: a role for novel bile acids and other (post-)transcriptional modulators?

Authors:  Ulrich Beuers; Gerd A Kullak-Ublick; Thomas Pusl; Erik R Rauws; Christian Rust
Journal:  Clin Rev Allergy Immunol       Date:  2009-02       Impact factor: 8.667

7.  Swertianlarin, an Herbal Agent Derived from Swertia mussotii Franch, Attenuates Liver Injury, Inflammation, and Cholestasis in Common Bile Duct-Ligated Rats.

Authors:  Liangjun Zhang; Ying Cheng; Xiaohuang Du; Sheng Chen; Xinchan Feng; Yu Gao; Shaoxue Li; Li Liu; Mei Yang; Lei Chen; Zhihong Peng; Yong Yang; Weizao Luo; Rongquan Wang; Wensheng Chen; Jin Chai
Journal:  Evid Based Complement Alternat Med       Date:  2015-07-27       Impact factor: 2.629

8.  Large dose means significant effect--dose and effect relationship of Chi-Dan-Tui-Huang decoction on alpha-naphthylisothiocyanate-induced cholestatic hepatitis in rats.

Authors:  Yanling Zhao; Xiao Ma; Jiabo Wang; Ruiqing Wen; Lei Jia; Yun Zhu; Ruisheng Li; Ruilin Wang; Jianyu Li; Lifu Wang; Yonggang Li; Xiaohe Xiao
Journal:  BMC Complement Altern Med       Date:  2015-04-02       Impact factor: 3.659

Review 9.  Primary biliary cirrhosis.

Authors:  Simon Hohenester; Ronald P J Oude-Elferink; Ulrich Beuers
Journal:  Semin Immunopathol       Date:  2009-07-15       Impact factor: 9.623

10.  Yinchenhao Decoction Ameliorates Alpha-Naphthylisothiocyanate Induced Intrahepatic Cholestasis in Rats by Regulating Phase II Metabolic Enzymes and Transporters.

Authors:  Ya-Xiong Yi; Yue Ding; Yong Zhang; Ning-Hui Ma; Feng Shi; Ping Kang; Zhen-Zhen Cai; Tong Zhang
Journal:  Front Pharmacol       Date:  2018-05-15       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.